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Abstract
The nature and occurrence of remission, and conversely, pharmacoresistance following epilepsy treatment is still not fully
understood in human or veterinary medicine. As such, predicting which patients will have good or poor treatment
outcomes is imprecise, impeding patient management. In the present study, we use a naturally occurring animal model of
pharmacoresistant epilepsy to investigate clinical risk factors associated with treatment outcome. Dogs with idiopathic
epilepsy, for which no underlying cause was identified, were treated at a canine epilepsy clinic and monitored following
discharge from a small animal referral hospital. Clinical data was gained via standardised owner questionnaires and
longitudinal follow up data was gained via telephone interview with the dogs’ owners. At follow up, 14% of treated dogs
were in seizure-free remission. Dogs that did not achieve remission were more likely to be male, and to have previously
experienced cluster seizures. Seizure frequency or the total number of seizures prior to treatment were not significant
predictors of pharmacoresistance, demonstrating that seizure density, that is, the temporal pattern of seizure activity, is a
more influential predictor of pharmacoresistance. These results are in line with clinical studies of human epilepsy, and
experimental rodent models of epilepsy, that patients experiencing episodes of high seizure density (cluster seizures), not
just a high seizure frequency pre-treatment, are at an increased risk of drug-refractoriness. These data provide further
evidence that the dog could be a useful naturally occurring epilepsy model in the study of pharmacoresistant epilepsy.
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Introduction
Epilepsy is the most common chronic neurological condition in
humans and dogs, with estimated prevalences of 0.4–1% [1] and
0.6%, respectively [2]. In human medicine, the best improvement
in Quality of Life (QoL) for epilepsy patients is achieved when
treatment leads to remission (seizure freedom) [3–5]. Indeed, in
one study, no significant change in QoL was found after treatment
for subjects that did not achieve seizure freedom [4]. In addition to
anti-epileptic drug (AED) therapy, surgical interventions are
utilised to achieve seizure freedom in medically intractable cases
[6]. The dog has been considered as a naturally occurring model
of human epilepsy [7,8]. There are considerable parallels in the
diagnosis of human and canine epilepsy, with similarly high levels
of workup, for example and the use of advanced diagnostic
imaging and in limited cases, the use of electroencephalography
(EEG) [9]. However, in veterinary medicine, most epilepsy trials
have primarily focused on reducing seizure frequency, rather than
achieving seizure freedom. Indeed, an $50% reduction in seizure
frequency has been the definition of AED efficacy in the majority
of canine epilepsy studies (e.g. [10–17]). This may not be a
satisfactory outcome for the carers (the owners), with nearly one
third considering only complete seizure freedom as an acceptable
outcome [18]. More than two thirds of dogs with epilepsy will
continue to have seizures long-term [19–22] and around 20–30%
will remain poorly controlled (,50% reduction of seizure
frequency) despite adequate treatment with phenobarbitone (PB)
and/or potassium bromide (KBr) [23–25]. Consequently, there is
a need to identify those dogs that are likely to have poor outcomes
so that owners have realistic, evidence-based expectations of their
dog’s treatment. This has been an area of focus in human epilepsy,
with analyses identifying risk factors for pharmacoresistance and
poor outcome (e.g. [26–28]). In contrast, it has been recognised
that more epidemiologic studies are needed to further document
the nature and occurrence of remission of epilepsy in dogs [29],
and identify risk factors associated with positive and negative
outcomes. For those dogs that are unresponsive to AEDs,
‘alternative’ non-pharmacological treatment options need to be
developed to improve their quantity and quality of life, for
example, dietary and surgical interventions [30].
Remission with or without medication has been observed in
canine epilepsy cases, demonstrating that epilepsy in dogs is not
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necessarily a lifelong condition. Remission rates vary between
studies, for example in a study of Danish Labrador Retrievers,
24% of dogs were classed as being in remission; with only 1 (6%) of
these receiving antiepileptic treatment (drug-induced remission)
[21]. In a further Danish study of 63 dogs with epilepsy, the
remission rate (both spontaneous remission and remission with
treatment) was 15% [22]. In these studies, remission was classified
as being seizure free for two years or three years seizure free,
respectively. In a Swiss study of Labrador Retrievers, 30% of dogs
treated with phenobarbitone became seizure-free, with an average
follow-up period of 4.8 years [19]. In a study of the efficacy of
phenobarbital compared with KBr as a first line treatment,
complete seizure freedom was achieved in 85% and 52%,
respectively, of treated dogs [31]. This study only lasted for six
months however, and it is possible that the percentage of dogs
experiencing seizure freedom would be lower given a longer
follow-up period. In addition, higher % treatment success rates
may reflect studying animals in first opinion practice environment,
where seizure phenotypes are likely to be less severe than animals
seen at referral practices.
Several factors related to the natural history of the disease and
clinical factors have been implicated in both the experimental and
clinical literature as influencing the likelihood of successful
treatment with AEDs (either remission or ,50% reduction in
seizure frequency). For example, recent rodent studies found that
early treatment [32] had a positive influence on the likelihood of
remission being achieved in certain types of epilepsy. Indeed, in
human epilepsy it was thought that patients should be treated with
AEDs immediately after a seizure to increase the likelihood of
achieving remission. However, evidence that remission rates in
countries with and without ready access to AEDs are similar [33]
implies that AEDs may act to suppress seizures, but have no
influence on achieving remission. In addition, there is increasing
evidence from both canine, rodent and human studies, that other
aspects of disease e.g. different markers of severity can influence
drug responsiveness and treatment outcome [19,29,34–36]. This
includes a high seizure frequency before treatment, and the
presence of cluster seizures and/or status epilepticus. Much of the
canine epilepsy literature in this area is derived from single breed
studies, thus the aim of this retrospective study was to investigate
factors associated with remission in a large population of dogs with
epilepsy treated at a multi-breed canine specific epilepsy clinic.
Materials and Methods
Data from dogs treated at a multi-breed canine specific epilepsy
clinic at the Royal Veterinary College Small Animal Referral
Hospital (RVC SARH) between 2005–2011 was retrospectively
collected from RVC’s electronic patient records. Clinical data was
originally gained via standardised owner questionnaires for
epilepsy patients at their first appointment, and longitudinal
follow up data was gained via telephone interview with the dogs’
owners. All dogs received a uniform diagnostic protocol (including
complete blood cell count; serum biochemical profile and dynamic
bile acid testing; MRI of the brain, 1.5-Tesla Gyroscan NT,
Philips Medical Systems) and a neurological examination to rule
out an underlying cause of the seizure activity. Only dogs which
were reported in the records to be diagnosed with idiopathic
epilepsy, for which a cause was not identified (no remarkable
findings on interictal neurological examination, haematology,
biochemistry, brain magnetic resonance imaging and cerebrospi-
nal fluid examination), were included in the study. A genetic or
hereditary basis cannot be confirmed for every case included in the
study, and it is possible that the cause could have been identified
with continuous EEG recording. Only dogs receiving AEDs were
included in the study.
Seizures were classified according to the former guidelines of the
International League Against Epilepsy, modified for veterinary
patients (Berendt and Gram, 1999; Licht et al., 2002). Epilepsy
was defined of at least two unprovoked seizures .24 h apart.
Cluster seizures were defined as an episode where more than one
seizure occurred within a 24 h period, with full recovery of
consciousness between seizures. Status epilepticus was defined as
seizure activity lasting longer than 10 min without gaining
consciousness. Seizure activity lasting less than 10 min without
gaining consciousness was classed as a single seizure episode. A
consistent history was collected with the help of a questionnaire
developed for a previous study [10]. The data collected included:
signalment, age presented to the hospital (days), age of dog at the
time of the first seizure (days), time until diagnosis (days), duration
of the disorder before treatment (days), number of seizures prior to
any treatment with an AED, seizure frequency per month before
medication, type of seizures experienced, and experience of cluster
seizures (yes/no) and status epilepticus (yes/no). Medication
administered was recorded, specifically whether phenobarbitone
(PB), potassium bromide (KBr) or other 3rd line drugs were
prescribed, and response to these drugs recorded as responsive or
unresponsive. Follow up time was recorded in days. Treatment
success was recorded as:
(i) Seizure-free remission (with or without medication) (1/0)
(ii) $50% reduction in seizure frequency (1/0)
Non-responsiveness to an AED was classified as a less than 50%
reduction in seizure frequency, despite being within the reference
range for the prescribed AED(s) and titrated to the maximum
tolerated effective dose. As these data were derived from a clinical
population, decision-making leading to the maximum dose of any
AED was made by both the clinician and the owner, taking into
account adverse effects of the drug and its efficacy. Serum levels of
phenobarbitone and/or potassium bromide were checked by the
attending clinician, and recorded from the clinical records where
available, to ensure the dog was within the reference range for
these AEDs and receiving adequate therapy, and to test the effect
of this variable.
Ethics statement
This study was approved by the Royal Veterinary College’s
Ethics and Welfare Committee. The owners of the dogs gave
permission for their animals to be used in this study.
Statistical analysis
Differences between outcome variables were tested with a
Fisher’s exact test for categorical variables with expected values ,
10, and the Pearson’s chi squared test for expected values .10.
The Mann-Whitney U-test was used for continuous variables.
Generalised linear mixed models for binary outcomes were then
used to identify risk factors in a multivariate analysis for successful
treatment outcomes, using the lmer function in R from the lme4
package. Treatment outcomes (i) seizure free remission with or
without medication (1/0) and (ii) $50% reduction in seizure
frequency (1/0) were used as the response variables in models.
Follow-up time and serum AED values were tested in the models
to verify that they did not have an effect on treatment success.
Breed was included as a random effect, with all cross breeds coded
plainly as ‘cross breed’ due to the unknown parentage of many of
these dogs. This random effect took into account the genetic non-
independence of multiple members of the same breed in the study
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population, and possible demographic and environmental factors.
Predictors including age, sex and neuter status were tested in all
models. Multicollinearity was checked for in all models, identified
from inflated standard errors in the models, and thus avoided.
Model fit was assessed using the deviance and Akaike’s informa-
tion criterion. Data is presented as median with 25th and 75th
percentiles and all tests were used two-sided with P,0.05 being
considered statistically significant.
Results
Population demographics
122 dogs were lost to follow and 344 dogs were included in the
analysis, of which 89.5% were pure bred and 10.5% were cross-
breeds. The five most common breeds were the Labrador
Retriever (14.8%), cross breed (10.5%), Border Collie (9.9%),
German Shepherd Dog (8.7%) and the Staffordshire Bull Terrier
(5.5%). The majority of dogs were male (70.3%), with 57% of all
dogs neutered. The median age (in days) at presentation to the
small animal referral hospital was 1260 days (720–2008) (approx-
imately 3.5 years).
Clinical data
The median age at onset of seizures was 780 days (360–1447.5).
The median time until diagnosis was 150 days (38–360), with the
median duration of the disorder before treatment 67.5 days (30–
180). The median number of seizures before the start of treatment
was 4.5 (3–7.25) with a median seizure frequency (per month)
before medication of 3 (1–5). The median follow up time was 656
days (330–960).
A minority of dogs had experienced status epilepticus (13.1%),
whereas nearly half of dogs had experienced cluster seizures (48%).
There was a significant association between the presence of status
epilepticus and cluster seizures (X2 = 8.05, P= 0.004), with 9.8% of
dogs experiencing both status epilepticus and cluster seizures.
There was no difference between male and female dogs
experiencing cluster seizures (48.9% vs. 45.8%; X2= 0.26,
P= 0.61); however, more male dogs experienced status epilepticus
than female dogs (15.5% vs. 5.2%; X2= 4.12, P= 0.041). At the
univariate level (Table 1) dogs without cluster seizures were
significantly more likely to go into remission, but there was no
difference in dogs with or without status epilepticus.
The most common seizure type was complex-focal seizures with
secondary tonic-clonic generalisation (35.7%), followed by gener-
alised tonic-clonic (32.6%), complex-focal (14.1%), and simple-
focal seizures with secondary tonic-clonic generalisation (13.7%).
The rarest seizure type was simple-focal seizures with only 11 cases
(3.8%).
Of the 113 dogs for which PB concentrations were available,
they were well within the reference range (29.161.60 mg/ml,
reference range from our laboratory of 15–45 mg/ml). KBr
concentrations were available for 53 dogs and were
1.6160.11 mg/ml, again well within the reference range from
our laboratory of 0.5–1.9 mg/ml.
The majority of dogs were receiving PB at follow up (67.2%),
with a further 38.4% of cases receiving KBr, and 27% of all cases
receiving PB and KBr in combination. A minority of cases (10.2%)
were prescribed a third line AED (e.g. gabapentin, pregabalin,
levetiracetam and zonisamide). In addition, 5.4% of cases received
Table 1. Association between clinical variables and being in seizure-free remission in canine epilepsy patients.
Remission Statistics
No (%) Yes (%) Fishers exact (2 sided) P
Sex Male 75.1 53.6 5.56 0.024
Female 24.9 46.4
Neuter status Neutered 53.2 75.0 4.53 0.038
Entire 46.8 25.0
Seizure severity Status
epilepticus
20.0 0.0 0.25 0.802
No Status
epilepticus
80.0 100.0
Cluster
seizures
62.8 17.9 19.63 ,0.001
No Cluster
seizures
37.2 82.1
Median (25th–75th percentile) Median (25th–75th percentile) Mann Whitney U P
Age presented to hospital
(days)
1080 (720–1800) 1440 (1080–2085) 1933 0.61
Time until diagnosis (days) 180 (62.3–378.8) 90 (15–225) 1204 0.79
Age at onset seizures (days) 720 (441–1286) 1170 (720–1725) 2971 0.026
Duration of disorder before
treatment (days)
90 (30–180) 60 (26–120) 578 0.31
Number of seizures before
start of treatment
5 (3–8.5) 4 (3–5.3) 1286 0.09
Seizure frequency per month
before medication
3 (1–6) 2 (1.25–3.75) 1582 0.39
doi:10.1371/journal.pone.0106026.t001
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emergency rectal diazepam treatment and 8.1% received pulsed
intermittent treatment with levetiracetam.
Risk factors for remission
Fourteen per cent of dogs were in remission on PB treatment.
When $50% reduction in seizure frequency is used as the
outcome measure, success rates are markedly higher with 64.5% of
dogs achieving this level of seizure reduction. At the univariate
level, several factors were associated with an increased likelihood
of achieving remission (Table 1), namely: being female, neutered,
no previous experience of cluster seizures and an older age at onset
of seizures. The same four factors were also associated with an
increased likelihood of achieving an $50% reduction in seizure
frequency, with the addition of an older age at presentation to
hospital (Table 2).
When tested in a multivariate mixed model (Table 3), two
categorical variables were significantly associated with the
likelihood of remission being achieved; sex and cluster seizures,
with female dogs over two times more likely to achieve remission,
and dogs with no previous experience of cluster seizures over six
times more likely to achieve remission. No effects of neuter status
or previous episodes of status epilepticus were found in any model,
and were not found to improve model fit (determined by Akaike
Information Criterion [AIC] and % correct classification), and as
such they were not included in the final model. There were no
significant effects of time until diagnosis, duration of time before
treatment, the number of seizures before treatment or the seizure
frequency per month before medication. No effects of follow up
time or serum AED values were found. There were no significant
effects of seizure type on the likelihood of remission (p = 0.208);
Table 2. Association between clinical variables and $50% reduction in seizure frequency in canine epilepsy patients.
$50% reduction Statistics
No (%) Yes (%) Fishers exact (2 sided) P
Sex Male 78.5 64.5 5.54 0.025
Female 21.5 35.5
Neuter status Neutered 50.0 63.2 3.62 0.040
Entire 50.0 36.8
Seizure severity Status
epilepticus
21.1 10.2 4.35 0.052
No Status
epilepticus
78.9 89.8
Cluster
seizures
71.7 33.5 34.01 ,0.001
No Cluster
seizures
28.3 66.5
Median (25th–75th percentile) Median (25th–75th percentile) Mann Whitney U P
Age presented to hospital
(days)
990 (720–1514.8) 1424.5 (840–2094.5) 5795 0.011
Time until diagnosis (days) 183 (72.5–360) 150 (34–360) 4225.5 0.216
Age at onset seizures (days) 720 (360–1125) 968 (447.8–1699) 9893 0.007
Duration of disorder before
treatment (days)
37.5 (22.5–142.5) 90 (30–180) 833.5 0.064
Number of seizures before
start of treatment
5 (3.3–8.8) 4.5 (3–7.8) 2762 0.276
Seizure frequency per
month before medication
3 (1–5) 2 (1–5) 5022.5 0.569
doi:10.1371/journal.pone.0106026.t002
Table 3. Risk factors for remission in canine epilepsy cases.
Predictor Odds Ratio (95% CI OR) SE (coef) Z P
Sex
Female 2.39 (1.01–5.64) 0.44 2.00 0.047
Male Ref
Cluster Seizures
No 6.08 (2.35–15.70) 0.49 3.75 ,0.001
Yes ref
doi:10.1371/journal.pone.0106026.t003
Drug Canine Epilepsy
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however the seizure types with the lowest remission rates were
simple-focal (0% remission) and complex-focal seizure with
secondary tonic-clonic generalisation (14.1% remission).
When an $50% reduction in seizure frequency is used as the
outcome measure (Table 2 and 4), the same two factors were
found to significantly predict the likelihood of achieving remission
in a multivariate model (Table 4), with the addition of age at onset
of seizures. As age at onset of seizures increases, the likelihood of
achieving an $50% reduction in seizure frequency increases.
Breeds
Dogs of fifteen different breeds achieved seizure freedom, and
dogs of fifty-two breeds achieved an $50% reduction in seizure
frequency. There was no statistically significant effect of breed on
the likelihood of dogs going into remission or having an $50%
reduction in seizure frequency when tested at the univariate level.
Of the breeds with over 10 dogs for which data was available (the
Labrador Retriever, Cross Breed, German Shepherd, Border
Collie and Staffordshire Bull Terrier), the breed least likely to go
into remission or have an $50% reduction in seizure frequency
was the Border Collie (0% and 40% respectively), followed by the
German Shepherd (11% and 35%) and Staffordshire Bull Terrier
(0% and 57%). Fishers exact tests revealed only significant effects
of being a Border Collie or German Shepherd on the likelihood of
entering remission or experiencing an $50% reduction in seizure
frequency (Table 5). When these breeds were included in
multivariate analyses as binary variables, no significant effects
were found.
Discussion
The results of this retrospective study provide evidence that the
presence of cluster seizures and thus seizure density (the temporal
pattern of seizure activity) is a more influential risk factor on the
likelihood of achieving remission in canine epilepsy than seizure
frequency or the total number of seizures prior to treatment.
Nearly half (48%) of dogs in the study population had experienced
cluster seizures, of which only 17.9% achieved remission and
33.5% achieved an $50% reduction in seizure frequency. This
result has previously been found in human epilepsy [37]. The
number of epileptic dogs that experience cluster seizures varies
between studies, with recent reports between 38% and 64%
[20,38]. The breed least likely to achieve remission in this study
was the Border Collie, a breed previously demonstrated to have a
higher level of cluster seizures than other breeds (84.6% affected)
[20], with similar levels reported in other studies (e.g. 94%; [29]).
A remission rate of 14.2% was observed in this study, similar to a
previous Danish study of canine epilepsy (15%) [22]. These were
both mixed study populations; however, in studies of Labrador
Retrievers in isolation, higher levels of remission have been
observed (24–40%) [19,21]. When .50% reduction in seizure
frequency is used as the outcome measure, success rates are
markedly higher at 64.5%.
Seizure density as well as frequency has been demonstrated to
influence the likelihood of remission in humans, with individuals
who experience an episode of status epilepticus [39–41], or cluster
seizures [37] less likely to go into remission. These results were also
seen in a recent study of predictors of pharmacoresistance in rats,
where the average seizure frequency per day of 13 rats
nonresponsive to medication was 4.31/day, indicating some rats
having cluster seizures [36]. This frequency was significantly
higher than 20 drug-responsive rats (mean 0.54/day). It is further
notable, that of the 13 rats that were unresponsive to medication, a
subgroup of six rats (18%) experienced high levels of cluster
seizures, with an average of 8.94 seizures per day [36]. Intact male
and female dogs have a higher likelihood of having cluster seizures
[42] which may have a negative impact on their prognosis.
Evidence from canine epilepsy is not clear however, with 89% (8/
9) of Border Collies in remission having a history of cluster
seizures, status epilepticus, or both [29]. A severe epilepsy
Table 4. Risk factors for an $50% reduction in seizure frequency in canine epilepsy cases.
Predictor Odds Ratio (95% CI OR) SE (coef) Z P
Sex
Female 2.15 (1.12–4.15) 0.33 2.32 0.021
Male ref
Cluster Seizures
No 4.66 (2.58–8.39) 0.30 5.14 ,0.001
Yes ref
Age at onset of seizures (days) 1.00 (1.00–1.01) 0.00 2.51 0.013
doi:10.1371/journal.pone.0106026.t004
Table 5. Top five breeds most likely to lack drug response.
Breed % remission p % $50% reduction P
Border Collie 0 0.02 40 0.01
German Shepherd 11 0.51 35 0.01
Staffordshire Bull Terrier 0 0.18 57 0.37
Cross Breed 19 0.30 61 0.38
Labrador Retriever 23 0.14 76 0.07
doi:10.1371/journal.pone.0106026.t005
Drug Canine Epilepsy
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phenotype is often seen in this breed, thus data from a larger
population with a diversity of breeds represented would be
valuable to gain an insight into this relationship in a wider
population with a variety of disease phenotypes.
No evidence was found to support the results of a recent rodent
study that found early treatment [32] influenced the likelihood of
remission being achieved. There are divergent opinions within the
veterinary profession regarding time to treatment after diagnosis of
epilepsy, a topic also debated in human medicine [43]. One school
of thought advises treatment of seizures as soon as a dog is
diagnosed as having recurrent seizures (i.e. after the second seizure
episode). However, the impact of AED side effects on QoL may be
considerable, with this being the top reason cited by owners for a
decreased QoL in their dogs (28% of 25 owners questioned) [44].
As such, the second school of thought considers that there should
be a balance between the benefits gained from using AEDs with
the potential adverse effects they cause. The results of this study
indicated no effect of time to treatment; however, there is mixed
evidence regarding its effects on treatment outcome. In clinical
studies of epilepsy in dogs, decreased time to treatment has not
been observed as a positive influence upon treatment outcome,
indeed, one study demonstrated that Labrador Retrievers that
were in remission received medication a longer period of time after
their first seizure than those dogs which continued to seizure [19].
It should be acknowledged that this result may be biased by
animals with a more severe seizure phenotype receiving treatment
earlier, due to owner and/or veterinarian concerns. It is currently
not veterinary practice to initiate treatment after the first seizure.
Early initation of treatment has also proven unsuccessful in several
human studies [45–47]. Time to treatment is additionally likely to
be influenced by disease severity, for example it was shorter in
dogs with episodes of status epilepticus [48], thus being
confounding factors in statistical analyses.
A large number of seizures before treatment has been identified
as a poor prognostic factor in several previous human studies of
epilepsy [34,41,49], with patients experiencing a greater number
of seizures prior to initiation of treatment more likely to have
refractory epilepsy. In rats, it was recently demonstrated that
seizure frequency in the early phase of epilepsy is a strong
predictor of refractoriness [36]. This has also been seen in dogs,
with refractory dogs having a significantly higher number of
seizures prior to presentation and beginning of treatment in
Labradors [19] and an initially higher seizure frequency in Border
Collies [29]. It has been discussed whether this initial high seizure
frequency and subsequent refractoriness may be an effect of
kindling (Reynolds, 1995). However, as time to treatment has not
been found to be a strong predictor of refractoriness in dogs and
humans, initial high seizure frequency has been considered more
likely to be the result, rather than the cause of the pathophysi-
ological changes that are later manifested as refractory epilepsy
[34,50]. Indeed, in this study and another previous study of canine
epilepsy, the number of seizures before treatment was not
significantly different between dogs positive vs. negative treatment
outcomes [48]. In addition, no effect was found of seizure type
upon the likelihood of remission; however, the most common
seizure type in dogs that did not achieve remission (39.6%) was
complex-focal seizures, also seen in human epilepsy [51,52],
adding evidence to the belief that focal seizures are more
challenging to treat.
Males were found to be less likely to achieve remission than
female dogs. Historically, male dogs are thought to seizure more
than female dogs [53], and recent epidemiological studies of
idiopathic epilepsy have confirmed a male overrepresentation for
this disorder [2,38]. With regard to the impact of sex upon
treatment outcome, little existing data is available. One study
noted that female dogs with epilepsy lived longer with the disorder
than male dogs, with a median age at death two years greater (8 vs.
6 years, respectively) [22]; however, this outcome measure may be
influenced by owner euthanasia decisions, so can only be a proxy
of treatment success. In previous studies, male dogs were found to
be more highly affected by cluster seizures than female dogs [42].
This result was not found in the current study, and indeed sex and
the presence of cluster seizures were found to be independently
significant risk factors, thus further investigation is warranted into
the effect of sex on treatment outcome.
Age at onset of disease was found to significantly influence the
likelihood of achieving an $50% reduction in seizure frequency,
with dogs experiencing their first seizure at an older age more
likely to achieve this level of reduction. This has previously been
demonstrated in Border Collies, with the mean age at onset
significantly higher in dogs with remission compared to those with
active epilepsy [29], and in Labradors, with dogs classed as having
excellent or good results (defined as those that were seizure-free, or
had an improvement in their seizure frequency, strength and/or
duration) having a significantly higher age at onset than
uncontrolled dogs [19]. Early age at seizure onset has been
previously identified in children to be a predictor of pharmacore-
sistance [54]. In contrast, in a study of canine juvenile epilepsy
(where the first seizure occurs before the age of one year), age at
onset had no influence on survival outcome [20].
There are recognised limitations to studying epilepsy in a
veterinary referral population [20] due to a bias towards a more
severe seizure phenotype, and thus may not be representative of
the whole canine epilepsy population. As such, further studies of
epilepsy in the first opinion practice population may be warranted,
although the level of diagnostic work up may be lower owing to
availability of equipment and specialist expertise, and thus
confidence in diagnosis may be variable. A further limitation of
this study is the varied follow up time of cases. In previous studies,
remission was strictly classified as dogs that were seizure free for
two or three years [21,22]. In human epilepsy, seizures may re-
occur after a period of months of seizure freedom, without
alterations to treatment [55]. As such, some of the dogs classified
as seizure free in this study may have later experienced seizures.
This may be due to a variety of factors including drug tolerance,
deterioration of the epilepsy phenotype, acquired drug resistance
and poor owner compliance [55]. The median follow up time,
however, was 656 days and thus is in line with the follow-up
standards of comparable epilepsy studies in the veterinary
environment. There are limitations to which variables could be
controlled for in this study, introduced by data being collected in a
clinical environment with naturally occurring disease in client
owned animals. Due to the expense of medication it is possible that
clients may decline third line AEDs that may affect the response
rate, which may mean the figures here are an underestimate of
how many dogs could biologically achieve remission. In addition,
EEG is not routinely used in the Canine Epilepsy Clinic data were
sourced from, or in veterinary medicine in general at present, and
thus there is no confirmation that the ‘seizure’ episodes reported
by owners was indeed seizure activity. A further limitation of this
study is that serum AED levels were not available for all dogs;
however, clinicians contributing to this dataset routinely checked
AED serum levels were within the reference ranges and thus, this
is naturally standardised across the sample. Furthermore, not all
serum levels were conducted at the same laboratory and therefore
could not be analysed in the same dataset. No statistical
association between AED levels and treatment outcome were
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found; however, future studies could include this variable to check
this result was not due to the lower power of this sub-sample.
Conclusions
In conclusion, the present provides evidence that it is not merely
the absolute number of seizures prior to treatment that predicts
refractoriness, but their temporal pattern, with those patients
experiencing cluster seizures (more than one seizure within a 24 h
period) more likely to be pharmacoresistant. Whether this result is
an effect of cluster seizures promoting epileptogenesis and causing
brain damage that results in seizures resistant to medication, or is
actually a reflection of a more aggressive disease phenotype that is
harder to treat is unknown, and warrants further investigation.
The present study further demonstrates similarities between this
naturally occurring model of epilepsy and both experimental
rodent models [36], and human clinical studies [37]. The
similarity between clinical environments, high level of diagnostic
work up, and shared living environments between humans and
dogs further strengthens the use of this readily available animal
model.
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